



IFW

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q90347

Toyohisa FUJIMOTO

Appln. No.: 10/552,036

Group Art Unit: 1712

Confirmation No.: 6985

Examiner: To be assigned

Filed: October 3, 2005

For: CURABLE COMPOSITION

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the document that is discussed below and a copy of which is attached, which the Examiner may deem material to patentability of the claims of the above-identified application.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicants submit the following explanations. In the Information Disclosure Statement filed on October 3, 2005, four foreign language documents were listed on the PTO/SB/08 A & B (modified) form. Applicants now enclose an English translation of a Notification of Transmittal of Translation of the International Preliminary Report on Patentability for PCT/JP2004/004481 (dated March 2, 2006), which includes the International

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: 10/552,036

Attorney Docket No. Q90347

Preliminary Report on Patentability with a Written Opinion of the International Searching Authority. The International Preliminary Report with its Written Opinion comprises a further concise statement of relevance with respect to the four foreign language documents that were listed in PTO/SB/08 A&B (modified) form filed with the Information Disclosure Statement of October 3, 2005.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.


INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: 10/552,036

Attorney Docket No. Q90347

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Sheldon I. Landsman

Registration No. 25,430

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: July 20, 1006